Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.
Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.
Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.
If left untreated, TTTS can have devastating consequences. Medical research indicates that:
TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.
Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.
Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.
Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:
Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.
Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.
Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.
According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.
When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.
Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.
Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."
Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.
Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.
The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

Credit: iStock
The World Health Organization (WHO) today announced its recommendations for the viral composition of influenza (or “flu”) vaccines for the 2027 southern hemisphere influenza season.
The announcement comes as US states can now order free COVID-19 vaccines for eligible children through the federal Vaccines for Children (VFC) program, following a nearly month-long delay.
Seasonal influenza causes substantial illness and hospitalizations each year. Because influenza viruses continually evolve, vaccine compositions need to be regularly updated.
WHO recommendations guide national vaccine regulators and manufacturers in developing and licensing vaccines for the following flu season.
"For nearly 75 years, the WHO Global Influenza Surveillance and Response System has demonstrated the power of global solidarity in public health," said Dr Maria Van Kerkhove, WHO's Director for Epidemic and Pandemic Management.
"The commitment of countries and laboratories to share data, viruses and expertise enables WHO to make timely vaccine recommendations, strengthening our collective ability to detect and respond to emerging influenza threats. This is global public health collaboration at its best," she added.
Also read: Fall Vaccines 2026: US Doctors Issue COVID, Flu And RSV Jab Guidance
From February through August 2026, influenza A(H1N1)pdm09, A(H3N2) and influenza B viruses circulated across regions. Influenza A viruses predominated in most regions, while influenza B dominated in Northern and Western Africa, North America and Eastern Asia.
WHO recommends the following strains for the 2027 southern hemisphere influenza season:
Egg-based vaccines
Cell culture-, recombinant protein- or nucleic acid-based vaccines
WHO also reviewed influenza viruses circulating in animals because of their potential to cause human infections and pandemics.
Read More: COVID-19 Rising In 35 US States: Sore Throat, Diarrhea Among Key Symptoms
The VFC program provides free immunizations to more than half of U.S. children, including those covered by Medicaid, uninsured or underinsured children, and Native Americans and Alaska Natives.
The FDA approved the updated COVID-19 vaccines on August 27, but access through the VFC program was delayed.
Although overall COVID-19 hospitalization rates remain low, they have been rising since mid-June. According to the CDC, hospitalization rates are highest among babies younger than 1 year old and adults aged 65 and older.
Public health officials from multiple states confirmed that they can now order the free vaccines.
South Carolina’s health department “was alerted yesterday afternoon by the CDC that COVID vaccines would be available for order today,” Casey White, a department spokeswoman, told CIDRAP News.
“Announcements will be shared with VFC providers and health departments to communicate the opening of ordering for all respiratory immunizations.”
WHO said it will issue its recommendation for vaccines for the 2027–28 northern hemisphere influenza season in February 2027.
Credit: iStock
Nearly 20 prescriptions for life-ending medication were reportedly issued in New York during the first month of its Medical Aid in Dying (MAiD) law, according to a Columbia University bioethics expert.
However, state health officials have not yet released data showing how many patients actually used the medication.
New York’s Medical Aid in Dying Act took effect on August 5, making it the 14th US state to legalize medical aid in dying.
David Hoffman, assistant professor of professional practice in bioethics at Columbia University, told The New York Post that conversations with doctors, hospitals and organizations indicated that about 20 prescriptions had been issued since the law took effect.
“The state will have the data on a rolling basis. It’s an after-the-fact analysis,” Hoffman told The Post.
The New York State Department of Health has yet to release precise figures on the program’s use.
Read More: Supreme Court Allows 1st Passive Euthanasia For Man In Vegetative State For 13 Years
The lack of publicly available data has drawn criticism from lawmakers who opposed the law. Upstate Republican Assemblyman Andrew Molitor told The New York Sun that New Yorkers should know how many people have requested and used medical aid in dying.
He said information should include patients’ socioeconomic status, insurance coverage, terminal condition, when prescriptions were filled and where the medication was administered.
Western New York Republican state Sen. George Borrello also criticized the wait for the state’s first annual report.
Critics have additionally raised concerns about whether the law could eventually be expanded. Borrello pointed to Canada, where medical assistance in dying was legalized in 2016.
Medical aid in dying remains controversial because it raises ethical, religious and moral questions. Critics warn about the potential coercion of vulnerable patients, while supporters emphasize personal autonomy and relief from prolonged, incurable suffering.
Medical aid in dying generally involves a patient voluntarily taking lethal medication prescribed by a doctor. Euthanasia, by contrast, involves a healthcare professional administering the lethal medication at the patient’s request.
Under New York’s law, patients must:
The law also requires a five-day waiting period between obtaining and dispensing the prescription.
Medical aid in dying requires the patient to take the prescribed medication themselves. This differs from euthanasia, in which a healthcare professional administers the life-ending medication.
Also read: Can Right To Die Be Practiced By Non-Terminally Ill Patients?
The law requires the state health commissioner to submit an annual report to the Legislature detailing the program’s use.
Hoffman noted that doctors report when medication is prescribed, but the state may not immediately know whether a patient ultimately takes it.
A New York State Department of Health spokesperson told The Post that the department will publish an annual report with utilization data as required by law.
Health Commissioner Dr. James McDonald said end-of-life decisions are “deeply personal” and should be made individually in consultation with patients, doctors, families and loved ones. The department has also issued guidance and proposed regulations intended to prevent misuse or inappropriate application of the law.
The debate over medical aid in dying extends beyond New York and the US.
France’s National Assembly recently gave final approval to a bill that would allow certain adults with incurable illnesses to receive lethal medication, following years of debate over end-of-life care.
Assisted-dying legislation is also being debated in the UK, where a bill covering England and Wales is returning to Parliament.
Credit: FDA/iStock
Vitruvias Therapeutics’ thyroid medication, recalled nationwide in August, has been elevated to the highest risk level by the US FDA.
The recall was issued because the medication may be superpotent, potentially causing hyperthyroidism (overactive thyroid).
On Wednesday, the FDA updated the recall to Class I, its most serious recall classification. It applies when there is a “reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.”
Also read: US Cancer Death Rates Fall For Men, Women: Lung Cancer Progress Drives Decline
The affected product is:
In its August 24 recall notice, the company said the tablets were potentially superpotent.
Millions of people with hypothyroidism rely on thyroid tablets every day to replace hormones their bodies cannot produce.
However, taking superpotent thyroid tablets can cause hyperthyroidism (overactive thyroid). It can force the body's metabolism into overdrive, speeding up organs and bodily functions.
Left untreated, this constant strain can cause serious health complications across multiple systems in the body.
In addition, people taking the medication can be at risk of
The lot was distributed nationwide in the US to Vitruvias Therapeutics’ direct accounts between January 31 and September 30, 2025. Of 3,655 units released, 1,955 were sold.
Read More: FDA Recalls Popular Thyroid Medication: What Levothyroxine Users Need to Know
The company identified the following groups as being at greater risk from superpotent thyroid tablets:
Excess thyroid hormones in older adults have been associated with adverse outcomes, particularly those affecting the heart.
Vitruvias Therapeutics said it has not received any reports of adverse events known to be linked to the recall.
The company is notifying wholesalers to stop distributing the recalled product and arranging for its destruction.
Patients taking Thyroid, USP from Lot 504950 should not stop taking it without first contacting their healthcare provider for guidance and/or a replacement prescription.
Speaking to HealthandMe, Dr Shruti Kotangale, Consultant Gynaecologist, Obstetrician and Infertility Expert at AIMS Hospital, Dombivli, explained that both conditions are commonly seen in women.
Hypothyroidism occurs when the thyroid is underactive. Symptoms can include tiredness, weight gain, dry skin, hair fall, constipation, feeling cold, a slow heartbeat and low mood or depression.
Hyperthyroidism occurs when the thyroid is overactive. Symptoms may include weight loss, a fast heartbeat, sweating, anxiety, tremors, irritability, frequent bowel movements and difficulty sleeping.
Women should seek medical attention and manage these symptoms without delay.
Thyroid disorders may cause a range of symptoms, including:
Diagnosis may involve:
© $2026 Times Horizon Private Limited